Skip to content
Search

Latest Stories

Pharmacists urged to participate in Oxford vaccine safety study

The Royal Pharmaceutical Society (RPS) has urged pharmacy teams to participate in an online survey as part of the Oxford/AstraZeneca vaccine safety study.

Conducted by the Drug Safety Research Unit (DSRU), the study will enroll at least 10,000 participants to assess the extent of side effects from the vaccine and how quickly they are recognised and acted upon.


The participants will include healthcare professionals and members of the public, who will be contacted at regular intervals after receiving the Oxford/AstraZeneca vaccine.

The pharmacies can register their interest in taking part in the study prior to receiving the vaccine or with 28 days of having the jab.

The DSRU is recruiting people from the Phase I vaccination group, which includes all those aged over 50, health and social care workers and people who are clinically extremely vulnerable.

The unit is also keen to get participants from all four UK countries to take part, whether or not they have experienced any symptoms after vaccination.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less